The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Should patients with smoldering myeloma be treated outside of the clinical trial setting?
Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, tackles the question of whether patients with smoldering myeloma, a precursor to active myeloma, should be treated before disease progression. Although Dr Hultcrantz only treats these patients within clinical trials, she acknowledges the high response rates to carfilzomib, lenalidomide, dexamethasone (KRd), and teclistamab, perhaps encouraging the treatment of these patients in the real world. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
